Literature DB >> 23801675

Exploratory evaluation of MR permeability with 18F-FDG PET mapping in pediatric brain tumors: a report from the Pediatric Brain Tumor Consortium.

Katherine A Zukotynski1, Frederic H Fahey, Sridhar Vajapeyam, Sarah S Ng, Mehmet Kocak, Sridharan Gururangan, Larry E Kun, Tina Y Poussaint.   

Abstract

UNLABELLED: The purpose of this study was to develop a method of registering (18)F-FDG PET with MR permeability images for investigating the correlation of (18)F-FDG uptake, permeability, and cerebral blood volume (CBV) in children with pediatric brain tumors and their relationship with outcome.
METHODS: Twenty-four children with brain tumors in a phase II study of bevacizumab and irinotecan underwent brain MR and (18)F-FDG PET within 2 wk. Tumor types included supratentorial high-grade astrocytoma (n = 7), low-grade glioma (n = 9), brain stem glioma (n = 4), medulloblastoma (n = 2), and ependymoma (n = 2). There were 33 cases (pretreatment only [n = 12], posttreatment only [n = 3], and both pretreatment [n = 9] and posttreatment [n = 9]). (18)F-FDG PET images were registered to MR images from the last time point of the T1 perfusion time series using mutual information. Three-dimensional regions of interest (ROIs) drawn on permeability images were automatically transferred to registered PET images. The quality of ROI registration was graded (1, excellent; 2, very good; 3, good; 4, fair; and 5, poor) by 3 independent experts. Spearman rank correlations were used to assess correlation of maximum tumor permeability (Kps(max)), maximum CBV (CBV(max)), and maximum (18)F-FDG uptake normalized to white matter (T/W(max)). Cox proportional hazards models were used to investigate associations of these parameters with progression-free survival (PFS).
RESULTS: The quality of ROI registration between PET and MR was good to excellent in 31 of 33 cases. There was no correlation of baseline Kps(max) with CBV(max) (Spearman rank correlation = 0.018 [P = 0.94]) or T/W(max) (Spearman rank correlation = 0.07 [P = 0.76]). Baseline CBV(max) was correlated with T/W(max) (Spearman rank correlation = 0.47 [P = 0.036]). Baseline Kps(max), CBV(max), and T/W(max) were not significantly associated with PFS (P = 0.42, hazard ratio [HR] = 0.97, 95% confidence interval [CI] = 0.90-1.045, and number of events [n(events)] = 15 for Kps(max); P = 0.41, HR = 0.989, 95% CI = 0.963-1.015, and n(events) = 14 for CBV(max); and P = 0.17, HR = 1.49, 95% CI = 0.856-2.378, and n(events) = 15 for T/W(max)).
CONCLUSION: (18)F-FDG PET and MR permeability images were successfully registered and compared across a spectrum of pediatric brain tumors. The lack of correlation between metabolism and permeability may be expected because these parameters characterize different molecular processes. The correlation of CBV and tumor metabolism may be related to an association with tumor grade. More patients are needed for a covariate analysis of these parameters and PFS by tumor histology.

Entities:  

Keywords:  18F-FDG PET; MR permeability; brain tumor; cerebral blood volume; pediatric

Mesh:

Substances:

Year:  2013        PMID: 23801675      PMCID: PMC4251761          DOI: 10.2967/jnumed.112.115782

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  28 in total

1.  Variability in PET quantitation within a multicenter consortium.

Authors:  Frederic H Fahey; Paul E Kinahan; Robert K Doot; Mehmet Kocak; Harold Thurston; Tina Young Poussaint
Journal:  Med Phys       Date:  2010-07       Impact factor: 4.071

2.  Relationship between PET-FDG and MRI apparent diffusion coefficients in brain tumors.

Authors:  B Palumbo; F Angotti; G D Marano
Journal:  Q J Nucl Med Mol Imaging       Date:  2008-07-30       Impact factor: 2.346

3.  Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium.

Authors:  Katherine A Zukotynski; Frederic H Fahey; Mehmet Kocak; Abass Alavi; Terence Z Wong; S Ted Treves; Barry L Shulkin; Daphne A Haas-Kogan; Jeffrey R Geyer; Sridhar Vajapeyam; James M Boyett; Larry E Kun; Tina Young Poussaint
Journal:  J Nucl Med       Date:  2011-01-13       Impact factor: 10.057

4.  Apparent diffusion coefficient of glial neoplasms: correlation with fluorodeoxyglucose-positron-emission tomography and gadolinium-enhanced MR imaging.

Authors:  A I Holodny; S Makeyev; B J Beattie; S Riad; R G Blasberg
Journal:  AJNR Am J Neuroradiol       Date:  2010-02-11       Impact factor: 3.825

5.  Establishment and results of a magnetic resonance quality assurance program for the pediatric brain tumor consortium.

Authors:  Robert V Mulkern; Peter Forbes; Kevin Dewey; Stravoula Osganian; Maureen Clark; Sharon Wong; Uma Ramamurthy; Larry Kun; Tina Young Poussaint
Journal:  Acad Radiol       Date:  2008-09       Impact factor: 3.173

6.  Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade.

Authors:  Meng Law; Stanley Yang; James S Babb; Edmond A Knopp; John G Golfinos; David Zagzag; Glyn Johnson
Journal:  AJNR Am J Neuroradiol       Date:  2004-05       Impact factor: 3.825

7.  Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography.

Authors:  G Di Chiro; R L DeLaPaz; R A Brooks; L Sokoloff; P L Kornblith; B H Smith; N J Patronas; C V Kufta; R M Kessler; G S Johnston; R G Manning; A P Wolf
Journal:  Neurology       Date:  1982-12       Impact factor: 9.910

8.  Exploratory evaluation of two-dimensional and three-dimensional methods of FDG PET quantification in pediatric anaplastic astrocytoma: a report from the Pediatric Brain Tumor Consortium (PBTC).

Authors:  Gethin Williams; Frederic H Fahey; S Ted Treves; Mehmet Kocak; Ian F Pollack; James M Boyett; Larry E Kun; Tina Young Poussaint
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-19       Impact factor: 9.236

9.  The value of positron emission tomography and proliferation index in predicting progression in low-grade astrocytomas of childhood.

Authors:  Michael C Kruer; Allen M Kaplan; Michael M Etzl; David F Carpentieri; Paul S Dickman; Kewei Chen; Kathleen Mathieson; Alison Irving
Journal:  J Neurooncol       Date:  2009-06-09       Impact factor: 4.130

10.  Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade.

Authors:  H C Roberts; T P Roberts; R C Brasch; W P Dillon
Journal:  AJNR Am J Neuroradiol       Date:  2000-05       Impact factor: 4.966

View more
  8 in total

Review 1.  Perfusion MRI as the predictive/prognostic and pharmacodynamic biomarkers in recurrent malignant glioma treated with bevacizumab: a systematic review and a time-to-event meta-analysis.

Authors:  Sang Hyun Choi; Seung Chai Jung; Kyung Won Kim; Ja Youn Lee; Yoonseok Choi; Seong Ho Park; Ho Sung Kim
Journal:  J Neurooncol       Date:  2016-04-23       Impact factor: 4.130

2.  Grading and outcome prediction of pediatric diffuse astrocytic tumors with diffusion and arterial spin labeling perfusion MRI in comparison with 18F-DOPA PET.

Authors:  Giovanni Morana; Arnoldo Piccardo; Domenico Tortora; Matteo Puntoni; Mariasavina Severino; Paolo Nozza; Marcello Ravegnani; Alessandro Consales; Samantha Mascelli; Alessandro Raso; Manlio Cabria; Antonio Verrico; Claudia Milanaccio; Andrea Rossi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-07-27       Impact factor: 9.236

3.  A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors.

Authors:  Mark W Kieran; Susan Chi; Stewart Goldman; Arzu Onar-Thomas; Tina Young Poussaint; Sridhar Vajapeyam; Frederic Fahey; Shengjie Wu; David C Turner; Clinton F Stewart; Marsha Moses; Roger J Packer; Regina Jakacki; Anu Banerjee; James M Boyett; Maryam Fouladi; Larry Kun
Journal:  Childs Nerv Syst       Date:  2015-07-19       Impact factor: 1.475

4.  Concurrent functional and metabolic assessment of brain tumors using hybrid PET/MR imaging.

Authors:  B Sacconi; R A Raad; J Lee; H Fine; D Kondziolka; J G Golfinos; J S Babb; R Jain
Journal:  J Neurooncol       Date:  2016-01-04       Impact factor: 4.130

5.  18F-FDG PET and MR imaging associations across a spectrum of pediatric brain tumors: a report from the pediatric brain tumor consortium.

Authors:  Katherine Zukotynski; Frederic Fahey; Mehmet Kocak; Larry Kun; James Boyett; Maryam Fouladi; Sridhar Vajapeyam; Ted Treves; Tina Y Poussaint
Journal:  J Nucl Med       Date:  2014-07-28       Impact factor: 10.057

Review 6.  Re-Examining the Need for Tissue Diagnosis in Pediatric Diffuse Intrinsic Pontine Gliomas: A Review.

Authors:  Libby Kosnik Infinger; Charles B Stevenson
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 7.  Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.

Authors:  Ziren Kong; Chengrui Yan; Ruizhe Zhu; Jiaru Wang; Yaning Wang; Yu Wang; Renzhi Wang; Feng Feng; Wenbin Ma
Journal:  Neuroimage Clin       Date:  2018-07-05       Impact factor: 4.881

Review 8.  The Role of PET in Supratentorial and Infratentorial Pediatric Brain Tumors.

Authors:  Angelina Cistaro; Domenico Albano; Pierpaolo Alongi; Riccardo Laudicella; Daniele Antonio Pizzuto; Giuseppe Formica; Cinzia Romagnolo; Federica Stracuzzi; Viviana Frantellizzi; Arnoldo Piccardo; Natale Quartuccio
Journal:  Curr Oncol       Date:  2021-07-05       Impact factor: 3.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.